Hydra

Quick links to important sections

Hydra

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydra

Property Description
Active ingredient Isoniazid (INH)
Forms Tablet, Oral Syrup, Injectable Solution
Pharmacological class Antitubercular Agent (Antimycobacterial)
Common Use Targeting Mycobacterium tuberculosis bacteria
Origin Synthetic Molecule

What is Hydra (Isoniazid) and What Type of Drug Is It?

The prescription medicinal product known commercially as Hydra contains the active substance Isoniazid (INH), which is classified as a first-line Antitubercular agent. Isoniazid is a synthetic compound, chemically known as isonicotinic acid hydrazide.

This drug is clinically recognized for its highly focused action, placing it within a specialized class of antibiotics dedicated to eliminating Mycobacterium species. Isoniazid's status as a first-line drug is critical, underscoring its essential role in initial therapeutic interventions against tuberculosis.


Composition, Origin, and Available Drug Forms

The composition of Hydra is based on the single active ingredient, Isoniazid. It is a synthetic molecule, derived entirely from chemical processes, which helps ensure high consistency. The medication is prepared in three main dosage forms: the most common tablet, an oral syrup, and an injectable solution for intravenous or intramuscular administration.

Isoniazid is a critical component in various fixed-dose combination products—like those containing Rifampin—demonstrating its utility in simplified multi-drug regimens designed to enhance patient adherence.


What is the General Therapeutic Purpose of Isoniazid?

The general therapeutic purpose of Isoniazid is the targeted eradication of the Mycobacterium tuberculosis organism. It functions as a bactericidal prodrug, meaning it becomes active only inside the bacteria. This active form specifically disrupts the formation of mycolic acids, unique fatty structures that protect the bacteria's cell wall. This mechanism provides the essential benefit of directly neutralizing the microbial source, which is fundamental to controlling the infection.

What side effects are possible with Hydra?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse reactions and safety characteristics of Isoniazid (Hydra), as mandated by government regulatory authorities. The structure and terminology are consistent with government-approved prescribing information, focusing strictly on reported effects and associated safety patterns.


Key Adverse Reaction Scope

Adverse reactions are primarily classified by frequency and by affected System-Organ Class (SOC), focusing most significantly on the Nervous System and the Hepatobiliary System.

Classification Example Adverse Reaction (Regulatory Terminology)
Very Common (≥ 1/10) Peripheral Neuropathy
Common (≥ 1/100 to < 1/10) Elevated Serum Transaminases (Liver Enzymes), Gastrointestinal Distress
Uncommon to Rare (< 1/100) Psychotic Reactions, Convulsions, Severe Cutaneous Adverse Reactions (SCAR)

Serious Adverse Reactions and Safety Constraints

The most significant serious risk documented in official labeling is Hepatotoxicity, which can manifest as severe, potentially fatal, fulminant hepatic failure. Severe liver injury is reported to occur most frequently during the first three months of treatment, though it may develop later, and the risk increases with age (35 years and older).

Other serious adverse reactions include severe forms of Peripheral Neuropathy, Agranulocytosis, and Aplastic Anemia.

Population-Specific Constraints: Isoniazid is explicitly contraindicated in individuals with a history of Isoniazid-associated liver injury or with severe hepatic impairment. Official safety notes also detail that the risk of neuropathy is elevated in individuals with poor nutritional status, chronic alcohol use, or co-morbidities like diabetes.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Hydra is a medical emergency that requires immediate professional intervention. According to authoritative regulatory documents, the profile of an overdose is primarily defined by severe, life-threatening effects on the respiratory and central nervous systems.

Documented Overdose Manifestations

Official labeling describes that overdose is characterized by respiratory depression, where breathing is significantly decreased in rate and/or volume, potentially leading to respiratory arrest. This is generally accompanied by profound Central Nervous System (CNS) depression, which may progress from extreme somnolence to stupor or coma.

Additional clinical signs documented in official labeling include miosis (pinpoint pupils), skeletal muscle flaccidity, and signs of cardiovascular compromise such as hypotension (low blood pressure) that can lead to circulatory collapse.

When to Seek Emergency Medical Help

Immediate emergency medical attention must be sought at the first recognized sign of a suspected overdose. The primary concern is the risk of death due to respiratory failure. Emergency action, when administered by professionals, focuses on establishing a patent airway and providing assisted ventilation. In a healthcare setting, the administration of a specific reversal agent may be considered.

Therapeutic Uses of Hydra

Hydra is commonly used across domains where short-term symptomatic assistance is appropriate, providing support that helps ease the overall burden of acute or recurrent episodes of discomfort. This class of medication is relevant in clinical settings marked by the heightened patient distress of pain, inflammation, and fever.

Hydra is generally applied in conditions where symptoms create noticeable interference with daily stability. It is relevant for easing symptoms related to physical discomfort, inflammatory or irritative states, and elevated body temperature. By addressing these symptoms, Hydra contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Physical Discomfort and Fever

The medication is helpful when groups of symptoms appear suddenly or fluctuate, such as during episodes of headache, muscle soreness, localized swelling, or general body aches associated with temporary illness. “Hydra is applied in addressing symptoms related to systemic imbalance, offering supportive relief when episodes become more noticeable.”

Regulatory References

  1. MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

The eligibility for using the medicine Hydra (Isoniazid) is strictly defined by regulatory authorities, focusing primarily on liver function and age-related risk. The medicine is approved for use in adults and pediatric populations typically aged three months and older.

Absolute Contraindications (Must Not Use)

Isoniazid is strictly contraindicated in patients with acute liver disease of any etiology or those with a documented history of isoniazid-associated hepatic injury. Use is also prohibited for individuals who have experienced previous severe adverse reactions to the drug, including signs of drug fever or hypersensitivity.

Conditional and Restricted Use

Regulatory labeling identifies populations who must only use the medicine under specific conditions or with increased monitoring:

Population Group Eligibility Status
Age Not recommended for infants aged 0 to 3 months due to lack of specific data. Risk of hepatitis increases significantly in patients over 35 years of age.
Organ Function/Comorbidity Caution is required for patients with chronic liver disease, severe renal dysfunction, diabetes mellitus, and convulsive disorders. Daily users of alcohol are at heightened risk of adverse effects.
Pregnancy/Lactation Use in pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. The drug passes into breast milk, requiring monitoring of the nursing infant.

What should I know about interactions with other medicines?

Hydra (Hydralazine/Hydrochlorothiazide) is a combination medication for hypertension, and its components can interact with several other drugs and substances, necessitating careful monitoring by a healthcare provider.

Major Interactions

Co-administration with other antihypertensive agents, such as ACE inhibitors (e.g., lisinopril), beta-blockers (e.g., metoprolol), or other vasodilators, can lead to additive hypotensive effects, resulting in a significant drop in blood pressure. Drugs that prolong the QT interval, a measure of the heart's electrical cycle, should be used cautiously with the hydrochlorothiazide component, as this combination may increase the risk of serious cardiac arrhythmias. High-dose lonafarnib (a CYP3A4 substrate) should typically be avoided as hydralazine may increase its levels and risk of toxicity.

Moderate Interactions

Nonsteroidal anti-inflammatory drugs (NSAIDs), including common pain relievers like ibuprofen or naproxen, may decrease the antihypertensive effect of Hydra. The use of corticosteroids (e.g., prednisone) may enhance the loss of electrolytes, such as potassium, due to the diuretic component. When taken concurrently with alcohol or other CNS depressants (e.g., barbiturates, benzodiazepines, certain antihistamines), the sedative effects and risk of low blood pressure may be intensified. Concomitant use with digoxin requires close monitoring of potassium and magnesium levels, as a diuretic-induced imbalance may increase the risk of digoxin toxicity. Lithium clearance is reduced by hydrochlorothiazide, which can increase lithium levels and the risk of toxicity, requiring dosage adjustments.

Mechanism of Action

How Hydra Works

Isoniazid (Hydra) functions as a prodrug, requiring internal enzymatic activation by the mycobacterial enzyme catalase-peroxidase ( KatG) after entering the cell. This specific conversion transforms the inert compound into the active INH-NAD inhibitor. This activation initiates a molecular cascade that leads to the disruption of the organism's structural integrity.

The INH-NAD inhibitor specifically blocks the InhA and KasA enzymes, shutting down the Mycolic Acid Biosynthesis Pathway. Mycolic acids are essential for building the cell's protective outer layer, so their absence compromises the entire cell wall structure. This structural defect leads to the bactericidal effect against actively multiplying organisms.

The mechanism's efficacy is constrained by bacterial genetics. Mutations in the katG gene can impair the necessary activation step, while over-expression of the target enzyme InhA can overcome the inhibitory effect. These limitations, alongside the mechanism’s dependency on the microbe's active growth rate, constrain the resulting bactericidal effect.

Dosage and Administration Information

How to Use Hydra (Isoniazid)

The usage of Isoniazid is defined by specific administration requirements, dosing schedules, and duration protocols. The medicine is primarily administered via the oral route as tablets or oral solution, with 100 mg and 300 mg being standard tablet strengths. The Intravenous (IV) or Intramuscular (IM) injection route is reserved for patients who cannot take the medication orally.

Isoniazid must be taken on an empty stomach—at least 1 hour before or 2 hours after a meal—to ensure optimal absorption.


Dosing and Schedule Patterns

The standard adult daily dose for active tuberculosis is 5 mg/kg of body weight once daily, with a maximum dose of 300 mg per day. An intermittent regimen of 15 mg/kg (up to 900 mg) is also utilized, administered 2 or 3 times per week. For the intermittent schedules, administration is conducted under Directly Observed Therapy (DOT) to verify adherence.

Pediatric dosing is higher on a weight-basis, typically 10 to 15 mg/kg once daily for children over 3 months.


Duration and Administration Notes

The overall use protocol for Isoniazid involves a 6 to 9 month duration, often comprising an initial multi-drug phase followed by a continuation phase. For certain patient groups, such as children or the malnourished, Pyridoxine (Vitamin B6) supplementation (e.g., 10 mg daily) is routinely co-administered. IV preparations must be diluted and infused over approximately 5 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hydra (Isoniazid)


Research Supporting Prevention of Latent Tuberculosis Infection (LTBI)

Research has widely examined the use of Isoniazid for people diagnosed with latent tuberculosis infection (LTBI). The primary goal of these studies is to see how the use of Isoniazid compares to either a placebo or other drug regimens in individuals at risk of developing active TB. The foundational evidence comes from large-scale Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. Researchers tracked outcomes by monitoring the rate at which participants developed active TB disease over several years. Isoniazid has consistently been included as a component in regimens studied for LTBI prevention. The overall body of evidence is documented by regulatory sources, providing context for the use of Isoniazid-containing regimens.


Research for Active, Drug-Susceptible Tuberculosis Disease

Isoniazid was evaluated in numerous foundational clinical trials as part of the initial multi-drug regimen for confirmed active, drug-susceptible tuberculosis (TB) disease. This research explored the measurement of outcomes in the standardized short-course multi-drug regimens used today. The key focus was to monitor the patients’ microbiological status, specifically tracking the measurement of sputum culture conversion. The evidence base for this core use is long-standing, derived from decades of large-scale research. The body of evidence for Isoniazid's inclusion in this standard regimen is used by regulatory bodies to inform protocol guidance.


Research on Isoniazid in Drug-Resistant Tuberculosis

Specialized research has explored the use of Isoniazid when the TB strain is confirmed to be mono-resistant. This evidence relies less on large RCTs and more on Systematic Reviews of Observational Cohort Studies. Because this evidence is drawn largely from observational settings, certainty remains low compared to core drug-susceptible indications. The findings were mixed across different studies and may depend on the specific genetic mechanism causing the resistance.


Areas of Research Uncertainty and Study Gaps

The evidence highlights several ongoing areas of uncertainty and research gaps.

  • Adherence: Research consistently notes that patient adherence to long-term regimens is a significant focus. Follow-up durations were limited in accurately documenting real-world adherence, meaning the Treatment Completion rates reported in trials may not reflect common clinical practice.
  • Subgroup Findings: Data for very specific clinical or genetic subgroups remain insufficient. Research does not determine whether an individual will respond similarly to the group average.
  • Long-term Effects: Long-term effects are not fully established beyond the multi-year follow-up periods defined in the key clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Hydra (FAQ)


Q: Are there any specific foods or drinks mentioned in the official information that I should avoid while taking Hydra?

A: Official patient information indicates that Hydra is a mild MAO inhibitor, meaning it has the potential to interact with tyramine-containing foods. Consuming foods like aged cheese, cured meats, or certain beans while taking this medicine is associated with a risk of adverse reactions such as headaches, flushing, or a rapid heart rate, according to regulatory warnings.


Q: What is the reason Hydra is not recommended for children?

A: Official documents describe that Hydra is included in treatment and prevention regimens for children. For pediatric use, official guidance often specifies a higher dose per kilogram of body weight compared to adults to ensure the medicine reaches adequate therapeutic levels.


Q: Is it necessary to take Hydra at the exact same time every day?

A: Official patient guides often suggest taking the medicine at about the same time every day for daily regimens. This practice is often suggested to support patient adherence and maintain consistent levels of the drug in the body over time.


Q: What is Hydra actually used for?

A: Hydra (Isoniazid) is officially classified as an antitubercular agent. According to regulatory approval, it is used specifically for the prevention and treatment of tuberculosis (TB).


Q: How quickly should I expect Hydra to start working?

A: Regulatory information on the drug's properties indicates that after being taken by mouth, Hydra typically reaches its peak concentration in the blood within 1 to 2 hours. However, clinical effectiveness in preventing or treating the disease is generally not an effect that is immediately observable.


Q: How long does one dose of Hydra stay in the body?

A: Official information regarding the drug's breakdown in the body states that the plasma elimination half-life can vary significantly based on a person's genetics. This half-life, which is the time it takes for half the drug to be eliminated, generally ranges from about 1.2 to 3.5 hours.


Q: Is it normal to feel [vague side effect like 'a little dizzy'] when starting Hydra?

A: Official safety information lists dizziness, clumsiness, or unsteadiness as potential, though less common, side effects. These symptoms are noted in official safety information as potential side effects associated with the medicine.


Q: What are the most commonly reported side effects of Hydra?

A: Common effects reported in official documents include a temporary increase in liver enzyme levels, peripheral neuropathy (tingling or numbness in the hands and feet), and stomach issues such as nausea and vomiting. Peripheral neuropathy is a common side effect described in official documents.


Q: Is Hydra known to cause any long-term health problems?

A: The medicine carries a serious Boxed Warning regarding the risk of severe and sometimes fatal hepatitis (liver damage). This serious side effect may develop even after many months of treatment, emphasizing the need for regular monitoring.


Q: Does Hydra interact negatively with common supplements like vitamin D or magnesium?

A: Official documents note that Hydra is known to interfere with the body’s metabolism of certain vitamins, especially Vitamin B6 (Pyridoxine) and Vitamin D. The potential interference with Vitamin B6 is why Pyridoxine (B6) is often included in treatment regimens to help prevent nerve-related side effects.


Q: Can people with kidney problems use Hydra?

A: Regulatory information advises that caution should be exercised in patients with impaired kidney function. Close monitoring may be recommended for these individuals to check for any increased risk of side effects, such as peripheral neuropathy.


Q: Is Hydra safe for use in older adults (senior population)?

A: Official warnings note that the risk of developing hepatitis is increased in older age groups (specifically noted for those 35 years and older). Special care and frequent monitoring are advised for these patients, although dose reduction is typically not noted as needed for age alone.


Q: Why do official documents mention [Specific Condition] as a reason not to take Hydra?

A: Official documents list acute hepatic disease (active liver disease) and previous severe adverse reactions to Hydra (including previous drug-induced liver disease) as contraindications. A contraindication is a medical condition or factor that serves as an official reason for avoiding its use.


Q: Is Hydra generally taken short-term or is it a long-term medication?

A: According to treatment guidelines and official documents, Hydra is typically prescribed as a long-term medication. Regimens for latent infection often last from 6 to 9 months, with treatment for active disease lasting longer as part of a multi-drug approach.


Q: Is Hydra a controlled substance?

A: Hydra (Isoniazid) is officially classified as a prescription medicine. However, it is generally not listed as a controlled substance by US or similar international drug enforcement authorities.


Q: Can Hydra be taken by someone who has a known allergy to other types of medicines?

A: Official patient information states that a known allergy to Hydra (Isoniazid) or any of its components is a contraindication.


Q: If I miss a dose of Hydra, what is the general recommendation for what to do?

A: Official patient guidance describes that a missed daily dose is generally taken as soon as it is remembered, unless it is close to the time for the next scheduled dose. Taking double doses is not advised.


Q: Does Hydra cause weight gain or weight loss, according to the studies?

A: Unexplained weight loss and loss of appetite are listed in official adverse effects lists. These symptoms are noted because they can sometimes be early warning signs of more serious liver problems that should be reported.


Q: Is it possible for Hydra to affect mood or cause any kind of anxiety?

A: Official safety information lists mental depression, anxiety symptoms, and changes in mood as potential, though rare, side effects that affect the central nervous system.


Q: Can I drive or operate machinery while taking Hydra, based on its safety profile?

A: Official patient information notes that caution is advised regarding driving or using heavy machinery until it is known how the medicine affects the individual. This caution is advised because Hydra may potentially cause dizziness or affect a person's alertness.


Q: Are there any warnings about combining Hydra with alcohol in the official label?

A: Official warnings explicitly state that the risk of developing hepatitis is increased with the daily consumption of alcohol. Official warnings note that patients are generally advised to strictly limit or completely avoid alcohol entirely.


Q: What is the official classification of Hydra (e.g., antibiotic, anti-inflammatory, etc.)?

A: Hydra is officially classified as an Anti-Infective Agent. More specifically, it is categorized as an Antitubercular Agent, meaning it is designed to fight tuberculosis.


Q: Why does Hydra have a warning label about [Specific Organ]? (e.g., liver or heart)

A: The medicine carries a major Boxed Warning concerning potential severe and sometimes fatal hepatitis (liver damage). This indicates that the liver is the specific organ that requires careful monitoring during treatment due to the severity of the risk.


Q: Is there a Black Box Warning associated with Hydra?

A: Yes, the medicine includes a Boxed Warning (the most serious warning required by the FDA). This warning specifically concerns the risk of severe and sometimes fatal hepatitis (liver damage).


Q: What should I know about Hydra if I have diabetes or high blood pressure?

A: Official documents note that diabetes mellitus is a condition requiring special care during treatment with Hydra. This is due to an increased risk of certain side effects, such as nerve damage (neuropathy). High blood pressure is generally not noted as a specific precaution.


Q: What is the mechanism of action of Hydra described as in plain language?

A: Official documents describe the drug as being bacteriostatic at low concentrations against the Mycobacterium tuberculosis bacteria. In simple terms, this means its primary function is to stop the growth and multiplication of the bacteria.


Q: Are headaches a common side effect of Hydra?

A: Headaches are listed among the potential adverse effects and are specifically a symptom associated with the potentially serious tyramine interaction with certain foods. They are also included among the less common general side effects.


Q: Is there any official guidance on what happens if too much Hydra is taken?

A: Official guidance on overdose management notes that specialized medical intervention may be required. Treatment in a healthcare setting may include procedures such as forced diuresis, haemodialysis, or peritoneal dialysis.


Q: Why do some people feel more energized or tired when they start taking Hydra?

A: Unusual tiredness or weakness is listed in official documents as a potential side effect. This fatigue is a symptom that should be monitored, as it can be an early indicator of liver problems.


Q: Is there a link between taking Hydra and a higher risk of infection?

A: Official safety documents note rare blood and lymphatic system disorders, including agranulocytosis and aplastic anaemia. These involve changes to blood cells that could potentially affect the body's ability to fight infection.


Q: Can Hydra be taken with medications for heartburn or acid reflux?

A: Patient information guides advise that antacids (which treat heartburn/acid reflux) should be taken 1 hour before or 2 hours after Hydra. This separation is necessary to prevent the antacids from interfering with how the body absorbs the medicine.


Q: What does it mean if Hydra is 'metabolized by the liver'?

A: Official information states that Hydra is metabolized (broken down) in the liver mainly by a process called acetylation. The speed of this process is genetically determined, meaning it varies from person to person and influences the amount of the drug in the body.


Q: Is Hydra associated with any changes in blood test results?

A: Yes, official documents note that Serum transaminase concentration (liver enzymes) becomes elevated in about 10% to 20% of patients. Because of this, patients are typically monitored with regular liver function tests.


Q: Can Hydra be safely used by people who are lactose intolerant?

A: The official Summary of Product Characteristics states that patients with rare hereditary problems such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption are advised not to take this medicine, likely due to the inactive ingredients.


Q: Is it true that Hydra is less effective in certain genetic populations?

A: Regulatory documents state that the rate at which Hydra is metabolized (acetylation) is genetically determined. People who metabolize the drug quickly (rapid acetylators) may have lower drug levels, which can influence how effective the treatment is.


Q: What is the pregnancy safety category for Hydra?

A: The medicine is classified as FDA pregnancy category C and TGA category A. Official documents state it is used during pregnancy only if the benefit is considered to outweigh the potential risk to the developing fetus.


Q: Can Hydra be crushed, split, or chewed?

A: Patient information for some tablet formulations may indicate they can be crushed and mixed with soft food if a person has difficulty swallowing, though they should generally be swallowed whole. Liquid forms are also available.


Q: What is the chemical name of the active ingredient in Hydra?

A: The chemical name of the active ingredient, Isoniazid, is Isonicotinic acid hydrazide or pyridine-4-carbohydrazide.

How should Hydra be stored and disposed of?

Storage and Handling of Isoniazid

Isoniazid (Hydra) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C. All dosage forms must be kept out of the sight and reach of children.

Dosage Form Mandatory Conditions Stability Constraint
Oral Tablets/Syrup Protect from excess moisture and heat; keep container tightly closed. Oral syrup must not be frozen and is stable for 1 month after opening.
Injection Store in the original carton to protect from light. Prepared solution must be used immediately.

Official Disposal Requirements

Unused or expired Isoniazid should be disposed of through a medicine take-back program if one is available. If unavailable, follow the procedure of mixing the product with an undesirable substance and discarding it in the trash, avoiding disposal into the sewage system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydra found in:

A-Z Index: